



## Enhanced expression of beta cell Ca(v)3.1 channels impairs insulin release and glucose homeostasis

Yu, J., Shi, Y., Zhao, K., Yang, G., Yu, L., Li, Y., Andersson, E-M., Ämmälä, C., Yang, S-N., & Berggren, P-O. (2020). Enhanced expression of beta cell Ca(v)3.1 channels impairs insulin release and glucose homeostasis. *Proceedings of the National Academy of Sciences*, 117(1), 448-453. <https://doi.org/10.1073/pnas.1908691117>

[Link to publication record in Ulster University Research Portal](#)

**Published in:**  
Proceedings of the National Academy of Sciences

**Publication Status:**  
Published (in print/issue): 07/01/2020

**DOI:**  
[10.1073/pnas.1908691117](https://doi.org/10.1073/pnas.1908691117)

**Document Version**  
Publisher's PDF, also known as Version of record

**General rights**  
Copyright for the publications made accessible via Ulster University's Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**  
The Research Portal is Ulster University's institutional repository that provides access to Ulster's research outputs. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [pure-support@ulster.ac.uk](mailto:pure-support@ulster.ac.uk).

# Enhanced expression of $\beta$ cell $\text{Ca}_v3.1$ channels impairs insulin release and glucose homeostasis

Jia Yu<sup>a,1,2</sup>, Yue Shi<sup>a,1</sup>, Kaixuan Zhao<sup>a</sup>, Guang Yang<sup>a,b</sup>, Lina Yu<sup>a</sup>, Yuxin Li<sup>c</sup>, Eva-Marie Andersson<sup>d</sup>, Carina Ämmälä<sup>d</sup>, Shao-Nian Yang<sup>a,c,2,3</sup>, and Per-Olof Berggren<sup>a,e,2,3</sup>

<sup>a</sup>The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, SE-171 76 Stockholm, Sweden; <sup>b</sup>Institute of Pharmacology, Jilin Academy of Traditional Chinese Medicine, Changchun 130021, China; <sup>c</sup>National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130024, China; <sup>d</sup>Bioscience, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 38 Mölndal, Gothenburg, Sweden; and <sup>e</sup>Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu 610041, China

Edited by Bruce M. Spiegelman, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, and approved November 26, 2019 (received for review May 20, 2019)

**Voltage-gated calcium 3.1 ( $\text{Ca}_v3.1$ ) channels are absent in healthy mouse  $\beta$  cells and mediate minor T-type  $\text{Ca}^{2+}$  currents in healthy rat and human  $\beta$  cells but become evident under diabetic conditions. Whether more active  $\text{Ca}_v3.1$  channels affect insulin secretion and glucose homeostasis remains enigmatic. We addressed this question by enhancing de novo expression of  $\beta$  cell  $\text{Ca}_v3.1$  channels and exploring the consequent impacts on dynamic insulin secretion and glucose homeostasis as well as underlying molecular mechanisms with a series of in vitro and in vivo approaches. We now demonstrate that a recombinant adenovirus encoding enhanced green fluorescent protein- $\text{Ca}_v3.1$  subunit (Ad-EGFP- $\text{Ca}_v3.1$ ) efficiently transduced rat and human islets as well as dispersed islet cells. The resulting  $\text{Ca}_v3.1$  channels conducted typical T-type  $\text{Ca}^{2+}$  currents, leading to an enhanced basal cytosolic-free  $\text{Ca}^{2+}$  concentration ( $[\text{Ca}^{2+}]_i$ ). Ad-EGFP- $\text{Ca}_v3.1$ -transduced islets released significantly less insulin under both the basal and first phases following glucose stimulation and could no longer normalize hyperglycemia in recipient rats rendered diabetic by streptozotocin treatment. Furthermore, Ad-EGFP- $\text{Ca}_v3.1$  transduction reduced phosphorylated FoxO1 in the cytoplasm of INS-1E cells, elevated FoxO1 nuclear retention, and decreased syntaxin 1A, SNAP-25, and synaptotagmin III. These effects were prevented by inhibiting  $\text{Ca}_v3.1$  channels or the  $\text{Ca}^{2+}$ -dependent phosphatase calcineurin. Enhanced expression of  $\beta$  cell  $\text{Ca}_v3.1$  channels therefore impairs insulin release and glucose homeostasis by means of initial excessive  $\text{Ca}^{2+}$  influx, subsequent activation of calcineurin, consequent dephosphorylation and nuclear retention of FoxO1, and eventual FoxO1-mediated down-regulation of  $\beta$  cell exocytotic proteins. The present work thus suggests an elevated expression of  $\text{Ca}_v3.1$  channels plays a significant role in diabetes pathogenesis.**

calcium channel | diabetes | exocytotic proteins | forkhead box O transcription factor | insulin secretion

**M**ultiple types of voltage-gated calcium ( $\text{Ca}_v$ ) channels, including  $\text{Ca}_v3.1$ , operate in the pancreatic  $\beta$  cell mediating  $\text{Ca}^{2+}$  influx in response to membrane depolarization evoked by increased blood glucose (1–7).  $\text{Ca}^{2+}$  influx through all types of  $\text{Ca}_v$  channels and  $\text{Ca}^{2+}$  mobilization mediated by intracellular  $\text{Ca}^{2+}$ -release channels in the  $\beta$  cell regulate glucose-stimulated insulin secretion (1, 5–8). In this context,  $\beta$  cell  $\text{Ca}_v1$  channels serve as a predominant player compared to other types of  $\beta$  cell  $\text{Ca}_v$  channels due to an optimal elevation in cytosolic free  $\text{Ca}^{2+}$  concentration ( $[\text{Ca}^{2+}]_i$ ) within exocytotic sites (1, 5–7). This optimally elevated  $[\text{Ca}^{2+}]_i$  allosterically initiates direct interactions between exocytotic proteins such as VAMP-2, synaptotagmins III and VII in the insulin granule membrane, and syntaxin 1A and SNAP-25 in the plasma membrane (5–7, 9). These interactions trigger fusion of insulin granules with the plasma membrane to form fusion pores for insulin cargo release in the first phase of glucose stimulation (5–7, 9). It is most likely that  $\text{Ca}^{2+}$  influx mediated by other types of  $\beta$  cell  $\text{Ca}_v$  channels mildly raises

$[\text{Ca}^{2+}]_i$  in regions which do not overlap well with exocytotic sites (5–7). This appears to facilitate trafficking of insulin granules to the readily releasable pool to be involved in late-phase but not early-phase glucose-stimulated insulin secretion (5–7). Although it has been suggested that physiological  $\text{Ca}^{2+}$  influx through  $\text{Ca}_v3$  channels participates in glucose-stimulated insulin secretion, the underlying mechanisms are not known (6, 7, 10, 11).

The  $\text{Ca}_v3.1$  channel is absent in healthy mouse  $\beta$  cells, whereas it resides in healthy rat and human  $\beta$  cells to conduct T-type  $\text{Ca}^{2+}$  currents, accounting for only a minor proportion of total  $\text{Ca}_v$  currents (6, 7, 10, 12, 13). T-type  $\text{Ca}^{2+}$  currents appear in diabetic mouse  $\beta$  cells and are significantly increased in diabetic rat  $\beta$  cells (14, 15). Despite little understanding of the physiological role of the  $\text{Ca}_v3.1$  channel in the  $\beta$  cell, there is a possibility that this  $\text{Ca}^{2+}$  channel affects expression of exocytotic proteins under diabetic conditions (6, 7).  $\text{Ca}^{2+}$ -dependent protein phosphatase calcineurin (CaN) undergoes activation when  $[\text{Ca}^{2+}]_i$  increases (16). Activated CaN may suppress the expression of exocytotic

## Significance

**We reveal that increased expression of  $\text{Ca}_v3.1$  channels in rat islets selectively impairs first-phase glucose-stimulated insulin secretion. This deterioration is recapitulated in human islets. Its causal role in diabetes development is clearly manifested in an in vivo diabetic model. Mechanistically, this is due to reduction of phosphorylated FoxO1 in the cytoplasm, elevated FoxO1 nuclear retention, and decreased syntaxin 1A, SNAP-25, and synaptotagmin III in a  $\text{Ca}_v3.1$  channel- and calcineurin-dependent manner. Our findings suggest that elevated expression of  $\text{Ca}_v3.1$  channels in pancreatic islets drives FoxO1-mediated down-regulation of exocytotic proteins resulting in the diabetic phenotypes of impaired insulin secretion and aberrant glucose homeostasis. This causal connection pinpoints  $\beta$  cell  $\text{Ca}_v3.1$  channels as a potential druggable target for antidiabetes therapy.**

Author contributions: J.Y., Y.S., S.-N.Y., and P.-O.B. designed research; J.Y., Y.S., K.Z., G.Y., L.Y., Y.L., and S.-N.Y. performed research; E.-M.A. and C.Ä. contributed new reagents/analytic tools; J.Y., Y.S., K.Z., G.Y., L.Y., Y.L., and S.-N.Y. analyzed data; and J.Y., S.-N.Y., and P.-O.B. wrote the paper.

Competing interest statement: P.-O.B. is the founder and CEO of the biotech company BioCrine AB. S.-N.Y. is a consultant for BioCrine AB.

This article is a PNAS Direct Submission.

This open access article is distributed under [Creative Commons Attribution License 4.0 \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).

<sup>1</sup>J.Y. and Y.S. contributed equally to this work.

<sup>2</sup>To whom correspondence may be addressed. Email: Jia.Yu@ki.se, Shao-Nian.Yang@ki.se, or Per-Olof.Berggren@ki.se.

<sup>3</sup>S.-N.Y. and P.-O.B. contributed equally to this work.

This article contains supporting information online at <https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1908691117/-DCSupplemental>.

First published December 23, 2019.


proteins through dephosphorylation of FoxO1 (17–19). Systemic administration of  $\text{Ca}_v3$  channel blockers significantly ameliorates hyperglycemia in diabetic mice (20). However, the causal role and transcriptomic impact of a pathological elevation of  $\beta$  cell  $\text{Ca}_v3.1$  channels in the development of diabetes is not known. We hypothesized that excessive  $\text{Ca}^{2+}$  influx through up-regulated  $\text{Ca}_v3.1$  channels drives  $\beta$  cell dedifferentiation by constitutively hyperactivating CaN and downstream FoxO1 signaling. This is likely to result in impaired expression of  $\beta$  cell exocytotic proteins, disturbed insulin secretion, aberrant glucose homeostasis, and consequent diabetes. Our results verify that the hypothesized signaling pathway indeed operates in  $\beta$  cells up-expressing  $\text{Ca}_v3.1$  channels, suggesting their important role in the pathogenesis of diabetes. This also means that  $\text{Ca}_v3.1$  channels may serve as potential druggable targets in the treatment of diabetes.

## Results and Discussion

**Ad-EGFP- $\text{Ca}_v3.1$  Efficiently Transduces COS-7 and Rat Islet Cells, and Expressed EGFP- $\text{Ca}_v3.1$  Conducts Typical T-Type  $\text{Ca}^{2+}$  Currents.** Recombinant adenovirus vectors have been verified to efficiently transduce islets (21). To elevate  $\text{Ca}_v3.1$  channel expression in rat islets, we constructed recombinant adenoviruses carrying either enhanced green fluorescent protein (Ad-EGFP) or the EGFP- $\text{Ca}_v3.1$  subunit (Ad-EGFP- $\text{Ca}_v3.1$ ) and characterized them in COS-7 cells. Ad-EGFP (SI Appendix, Fig. S1 A, Top) and Ad-EGFP- $\text{Ca}_v3.1$  (SI Appendix, Fig. S1 A, Bottom) were efficiently expressed in COS-7 cells. Ad-EGFP- $\text{Ca}_v3.1$ -positive cells displayed typical T-type  $\text{Ca}^{2+}$  currents characterized by tiny unitary conductance and fast inactivation (SI Appendix, Fig. S1 B, Right), whereas Ad-EGFP-positive cells showed no  $\text{Ca}^{2+}$  currents (SI Appendix, Fig. S1 B, Left). Furthermore, the former cells expressed genuine whole-cell T-type  $\text{Ca}^{2+}$  currents, which were transiently activated at more negative membrane potentials (SI Appendix, Fig. S1 C, third and fourth panels), but the latter cells did not (SI Appendix, Fig. S1 C, second panel). The effective expression and adequate functionality of Ad-EGFP- $\text{Ca}_v3.1$  in COS-7 cells offer a promising basis for elevation of  $\text{Ca}_v3.1$  channels in rat islets.

We characterized expression and functionality of Ad-EGFP- $\text{Ca}_v3.1$  in dispersed rat islet cells using the same experimental approaches as employed in the above experiments. We observed that both Ad-EGFP-infected (SI Appendix, Fig. S2, Top) and Ad-EGFP- $\text{Ca}_v3.1$ -infected islet cells (SI Appendix, Fig. S2, Bottom) emitted intense EGFP fluorescence. This substantiates that these recombinant adenoviral vectors can effectively express the EGFP and  $\text{Ca}_v3.1$  genes in these cells. We also visualized 2 inward current components, peaking at about  $-45$  and  $-5$  mV, in control cells and cells transduced with Ad-EGFP- or Ad-EGFP- $\text{Ca}_v3.1$  (Fig. 1 A). The first component, i.e., low  $\text{Ca}_v$  currents, was significantly greater in Ad-EGFP- $\text{Ca}_v3.1$ -treated cells than in control cells or cells infected with Ad-EGFP (Fig. 1 A and B). However, there was no obvious difference in the second component, namely, high  $\text{Ca}_v$  currents, between these 3 types of cells (Fig. 1 A and B). The data reveal that Ad-EGFP- $\text{Ca}_v3.1$  can satisfactorily transduce dispersed rat islet cells and compel these cells to additionally express functional  $\text{Ca}_v3.1$  channels, thereby enhancing T-type  $\text{Ca}^{2+}$  currents.

It should be pointed out that we rarely visualized EGFP fluorescence in the plasma membrane of EGFP- $\text{Ca}_v3.1$ -positive COS-7 (SI Appendix, Fig. S1 A) and islet cells (SI Appendix, Fig. S2). Nevertheless, we could exclusively detect whole-cell T-type  $\text{Ca}^{2+}$  currents in these cells. This is due to the fact that a limited number of EGFP- $\text{Ca}_v3.1$  channels scatter throughout the plasma membrane and have a low probability of appearing in the tiny proportion of the plasma membrane in the focal plane of the confocal microscope.



**Fig. 1.** Effects of Ad-EGFP- $\text{Ca}_v3.1$  transduction on whole-cell  $\text{Ca}_v$  currents in dispersed islet cells and on glucose-stimulated insulin secretion and  $[\text{Ca}^{2+}]_i$  in islets. (A) Sample whole-cell  $\text{Ca}_v$  current traces from a control rat islet cell and a rat islet cell transduced with Ad-EGFP or Ad-EGFP- $\text{Ca}_v3.1$ . (B) Average  $\text{Ca}^{2+}$  current density–voltage relationships in control (n = 13), Ad-EGFP (n = 11), and Ad-EGFP- $\text{Ca}_v3.1$  (n = 12) groups.  $^{**}P < 0.01$  vs. control and Ad-EGFP. (C and D) Dynamic insulin secretion from control, Ad-EGFP-transduced, and Ad-EGFP- $\text{Ca}_v3.1$ -transduced rat (C) and human (D) islets perfused with 3 mM glucose (3G) followed by 16.7 mM glucose (16.7G).  $^{**}P < 0.01$  and  $^{*}P < 0.05$  vs. control and Ad-EGFP. Control rat islets (n = 13), Ad-EGFP-transduced rat islets (n = 10), Ad-EGFP- $\text{Ca}_v3.1$ -transduced rat islets (n = 10), Ad-EGFP-transduced human islets (n = 6), and Ad-EGFP- $\text{Ca}_v3.1$ -transduced human islets (n = 6). (E) Sample  $[\text{Ca}^{2+}]_i$  traces registered in Ad-EGFP- and Ad-EGFP- $\text{Ca}_v3.1$ -transduced rat (Upper) and human (Lower) islets following perfusion with 3 mM (3G) and 16.7 mM glucose (16.7 G) as well as 25 mM KCl (25K). (F) Quantitative analysis of average fura-2 F340/F380 ratios during exposure to 3 mM glucose and stimulation with 16.7 mM glucose and peak fura-2 F340/F380 ratios in response to 25 mM KCl in Ad-EGFP-transduced (n = 12) and Ad-EGFP- $\text{Ca}_v3.1$ -transduced (n = 13) rat islets (Upper) and human islets (n = 9 for Ad-EGFP and n = 12 for Ad-EGFP- $\text{Ca}_v3.1$ ) (Lower).  $^{**}P < 0.01$  and  $^{*}P < 0.05$  vs. Ad-EGFP.


**Ad-EGFP- $\text{Ca}_v3.1$ -Transduced Islets Display Impairments in Both Basal and First-Phase Glucose-Stimulated Insulin Secretion and Elevation in Basal  $[\text{Ca}^{2+}]_i$ .** Successful transduction of COS-7 and dispersed islet cells does not necessarily mean that the same thing should happen in intact islets, which are more difficult to transduce (22). Therefore, we evaluated the efficiency of infection of rat and human islets with Ad-EGFP- $\text{Ca}_v3.1$ . Both Ad-EGFP (SI Appendix, Fig. S3 A and B, Top 2 panels) and Ad-EGFP- $\text{Ca}_v3.1$  (SI Appendix,

Fig. S3 *A* and *B*, Bottom 2 panels) satisfactorily infected islet cells within intact islets that emit intense EGFP fluorescence. This means that the  $\text{Ca}_v3.1$  gene in Ad-EGFP- $\text{Ca}_v3.1$  can be efficiently expressed in cells within intact islets. Pancreatic  $\beta$  cells are specialized for glucose-stimulated insulin secretion (6, 7, 12). The importance of any molecular constituent of the  $\beta$  cell should be reflected upon by the extent and severity of impairment in glucose-stimulated insulin secretion when altered. To explore the importance of  $\text{Ca}_v3.1$  channels in  $\beta$  cells, we analyzed dynamic glucose-stimulated insulin secretion from rat and human islets transduced with Ad-EGFP- $\text{Ca}_v3.1$ . Ad-EGFP- $\text{Ca}_v3.1$ -transduced islets released significantly less insulin during perfusion with 3 mM glucose compared to control islets and islets treated with Ad-EGFP (Fig. 1 *C* and *D*). Importantly, Ad-EGFP- $\text{Ca}_v3.1$ -transduced islets displayed a selective impairment in first-phase glucose-stimulated insulin secretion with intact second-phase insulin response when exposed to 16.7 mM glucose (Fig. 1 *C* and *D*). Moreover, elevated expression of  $\beta$  cell  $\text{Ca}_v3.1$  channels impaired glucose-stimulated insulin secretion not only from rat but also human islets. These data suggest that the pathologically enhanced expression of  $\beta$  cell  $\text{Ca}_v3.1$  channels serves as a causal factor for defective insulin secretion from human and rodent islets, regardless of obvious interspecies differences in expression of  $\text{Ca}_v3.1$  channels in healthy  $\beta$  cells (6, 7, 10, 12, 13). This is well supported by the findings of the appearance of T-type  $\text{Ca}^{2+}$  currents in diabetic mouse  $\beta$  cells, elevation of these  $\text{Ca}^{2+}$  currents in diabetic rat  $\beta$  cells, and, in particular, amelioration of hyperglycemia by systemic inhibition of these  $\text{Ca}^{2+}$  currents in diabetic mice (6, 7, 12, 14, 15, 20). Taken together, the findings indicate the significance of up-regulation of  $\beta$  cell  $\text{Ca}_v3.1$  channels in the pathogenesis of human diabetes.

$\text{Ca}_v3.1$  channels exist primarily for mediating  $\text{Ca}^{2+}$  influx into the cytosolic compartment to participate in the formation of  $[\text{Ca}^{2+}]_i$


dynamics that regulates glucose-stimulated insulin secretion and maintains  $\beta$  cell specificity (1, 5–7). This prompted us to examine whether Ad-EGFP- $\text{Ca}_v3.1$  transduction altered  $[\text{Ca}^{2+}]_i$  dynamics, leading to impaired glucose-stimulated insulin secretion. It turned out that both Ad-EGFP- $\text{Ca}_v3.1$ -transduced rat and human islets showed significant elevations in  $[\text{Ca}^{2+}]_i$  during perfusion with 3 mM glucose and stimulation with 16.7 mM glucose or 25 mM KCl compared to those treated with Ad-EGFP (Fig. 1 *E* and *F*).  $[\text{Ca}^{2+}]_i$  curves registered from Ad-EGFP- $\text{Ca}_v3.1$ -transduced islets were shifted upwards in comparison to those from islets transduced with Ad-EGFP (Fig. 1 *E* and *F*). These results substantiate the importance of the up-expressed  $\text{Ca}_v3.1$  channels in rearranging  $[\text{Ca}^{2+}]_i$  dynamics and thereby elevation in  $[\text{Ca}^{2+}]_i$  in islets. However, intuitively, such an elevation in  $[\text{Ca}^{2+}]_i$  should promote insulin secretion by allosterically triggering  $\text{Ca}^{2+}$ -dependent SNARE interactions (23–25). This suggests that elevated  $[\text{Ca}^{2+}]_i$  in Ad-EGFP- $\text{Ca}_v3.1$ -transduced islets may switch on other mechanisms to impair insulin secretion. Previous studies indicate the possibility that the elevation in basal  $[\text{Ca}^{2+}]_i$  following Ad-EGFP- $\text{Ca}_v3.1$  transduction may activate CaN to dephosphorylate FoxO1, inducing its nuclear retention and down-regulation of some exocytotic proteins (17–19).

**Islets Transduced with Ad-EGFP- $\text{Ca}_v3.1$  Lose Their Ability to Normalize Hyperglycemia in Streptozotocin-Induced Diabetic Rats.** The impairment of first-phase glucose-stimulated insulin secretion represents the initial defect of  $\beta$  cell function and plays an important role in glucose intolerance during diabetes development (26–28). This prompted us to investigate the *in vivo* pathological role of Ad-EGFP- $\text{Ca}_v3.1$ -transduced islets that exhibited defective basal insulin release and first-phase glucose-stimulated insulin secretion. We compared the abilities of control, Ad-EGFP-infected, and



**Fig. 2.** Effects of Ad-EGFP- $\text{Ca}_v3.1$  transduction on antihyperglycemic ability of islets transplanted into the anterior chamber of the eye (ACE) of rats rendered diabetic with STZ injection. (A) Experimental protocol illustrating time points of STZ injection, islet transplantation, blood glucose test, and *in vivo* microscopy. (B) Stereomicroscopic photographs showing aggregated islets engrafted on the rat iris illuminated by visible light (Left) and EGFP fluorescence from these islet aggregates detected using the GFP filter set (Right). Control, Ad-EGFP-transduced, and Ad-EGFP- $\text{Ca}_v3.1$ -transduced islets are shown in the Top, Middle, and Bottom microphotographs, respectively. (Scale bars, 1 mm.) (C) Sample confocal images (Left) of control (Top microphotograph), Ad-EGFP-transduced (Middle microphotograph), and Ad-EGFP- $\text{Ca}_v3.1$ -transduced (Bottom microphotograph) islets engrafted on the rat iris. Green and red represent EGFP fluorescence from Ad-EGFP- and Ad-EGFP- $\text{Ca}_v3.1$ -transduced islets and Texas Red fluorescence from vasculatures filled with 70 kDa dextran-conjugated Texas Red, respectively. Corresponding reflected-light images (Right) of control (Top microphotograph), Ad-EGFP-transduced (Middle microphotograph), and Ad-EGFP- $\text{Ca}_v3.1$ -transduced (Bottom microphotograph) islets engrafted on the rat iris. (Scale bars, 50  $\mu\text{m}$ .) (D) Quantifications of blood glucose levels in STZ-treated rats transplanted with control islets ( $n = 6$ ) and islets transduced with Ad-EGFP ( $n = 6$ ) or Ad-EGFP- $\text{Ca}_v3.1$  ( $n = 6$ ) before and after STZ injection and 4 wk after islet transplantation.  $^{**}P < 0.01$  vs. Ad-EGFP- $\text{Ca}_v3.1$ .





Ad-EGFP- $\text{Ca}_v3.1$ -infected islets to ameliorate hyperglycemia in streptozotocin (STZ)-induced diabetic rats. These 3 groups of islets were transplanted into the anterior chamber of the eye of STZ-treated rats (Fig. 2A). All of them were well engrafted on the iris and richly vascularized within 4 wk after transplantation, during which both Ad-EGFP- $\text{Ca}_v3.1$ - and Ad-EGFP-treated islets emitted appreciable EGFP fluorescence (Fig. 2B and C). STZ-treated rats manifested overt hyperglycemia before islet transplantation (Fig. 2D). Importantly, a significant normalization of hyperglycemia occurred in STZ-treated rats transplanted with either control islets or islets infected with Ad-EGFP but not in STZ-treated rats transplanted with Ad-EGFP- $\text{Ca}_v3.1$ -transduced islets (Fig. 2D). Indeed, Ad-EGFP- $\text{Ca}_v3.1$ -treated islets have no ability to ameliorate hyperglycemia in STZ-induced diabetic rats. Of note, no appreciable differences were found in the islet backscatter signal, which reflects functional islet cell mass (29), between control, Ad-EGFP-transduced, and Ad-EGFP- $\text{Ca}_v3.1$ -transduced islets (Fig. 2C). This indicates that the enhanced expression of  $\beta$  cell  $\text{Ca}_v3.1$  channels did not reach the extremely high level where these channels mediate exaggerated  $\text{Ca}^{2+}$  influx to cause  $\text{Ca}^{2+}$ -dependent islet cell damage, such as reduced insulin content, apoptosis, and necrosis.


**Transduction with Ad-EGFP- $\text{Ca}_v3.1$  Decreases Cytoplasmic p-FoxO1 and Induces FoxO1 Nuclear Retention through the  $\text{Ca}_v3.1$  Channel-Dependent Activation of Calcineurin.** The unique ability of  $\beta$  cells to accurately release insulin in response to glucose critically relies on adequate expression of  $\beta$  cell-specific genes under the control of a defined set of transcription factors, including FoxO1 (18, 30, 31). This transcription factor acts not only downstream of complex  $\text{Ca}^{2+}$  signaling systems but also upstream of expression of  $\beta$  cell exocytotic proteins (18, 31). This made us question if elevated expression of  $\text{Ca}_v3.1$  channels and resulting  $\text{Ca}^{2+}$  influx interfere with FoxO1 transcriptional action on  $\beta$  cell exocytotic protein genes with consequent impaired glucose-stimulated insulin secretion. We therefore quantified cytoplasmic phosphorylated FoxO1 in insulin-secreting INS-1E cells subjected to different treatments. It turned out that the relative abundance of cytoplasmic phosphorylated FoxO1 was significantly reduced in the Ad-EGFP- $\text{Ca}_v3.1$  group in comparison to that in the control and the Ad-EGFP groups as well as the group subjected to Ad-EGFP- $\text{Ca}_v3.1$  infection followed by exposure to the highly selective  $\text{Ca}_v3$  channel blocker NNC55-0396 (Fig. 3A and B). All 4 groups exhibited similar intensities of GAPDH immunoreactivity (Fig. 3A). The reduction of cytoplasmic phosphorylated FoxO1 induced by elevated expression of  $\text{Ca}_v3.1$  channels reflects decreased phosphorylation and increased retention of FoxO1 in the nucleus and suggests that the expression of  $\beta$  cell exocytotic protein genes downstream of FoxO1 is reduced.

To detect up-expressed  $\text{Ca}_v3.1$  channel-induced changes in FoxO1 subcellular distribution and underlying mechanisms, we immunocytochemically characterized cytoplasmic and nuclear FoxO1 in INS-1E cells following Ad-EGFP- $\text{Ca}_v3.1$  transduction and treatment with NNC55-0396 or the CaN inhibitor tacrolimus. Fig. 3C and E shows that FoxO1 immunofluorescence was more intense in the nuclei but less intense in the cytoplasm of cells transduced with Ad-EGFP- $\text{Ca}_v3.1$  than in those of Ad-EGFP-transduced cells. As shown in Fig. 3D and F, the ratio of nuclear to cytoplasmic FoxO1 in the Ad-EGFP- $\text{Ca}_v3.1$  group significantly increased compared to that in Ad-EGFP group. Importantly, the effects were effectively ablated by treatment with NNC55-0396 or tacrolimus (Fig. 3C–F). These results demonstrate that Ad-EGFP- $\text{Ca}_v3.1$  transduction indeed gives rise to FoxO1 nuclear retention through the  $\text{Ca}_v3.1$  channel-dependent activation of CaN. They also suggest that the up-expressed  $\text{Ca}_v3.1$ -mediated  $\text{Ca}^{2+}$  influx is likely to constitutively hyperactivate CaN to make this phosphatase powerful enough to reach and dephosphorylate nuclear p-FoxO1, thereby preventing it from being extruded from the nucleus. In fact,

the constitutively hyperactivated CaN has been demonstrated to dephosphorylate serine-256 of FoxO1 in ischemic neurons where  $[\text{Ca}^{2+}]_i$  is pathologically high (17, 32).

**Ad-EGFP- $\text{Ca}_v3.1$  Transduction Reduces Syntaxin 1A, SNAP-25, and Synaptotagmin III in a  $\text{Ca}_v3.1$  Channel-Dependent Manner.** To verify if FoxO1 nuclear retention induced by up-expressed  $\text{Ca}_v3.1$  channels reduces expression of  $\beta$  cell exocytotic protein genes, we performed immunoquantification of syntaxin 1A, SNAP-25, and synaptotagmins III and VII in rat islets and INS-1E cells. Immunoblot analysis shows that Ad-EGFP- $\text{Ca}_v3.1$ -treated islets gave significantly weaker intensities of synaptotagmin III-, syntaxin 1A-, and SNAP-25-immunoreactive bands in comparison to control and Ad-EGFP-treated islets (Fig. 3G and H). These 3 types of islets exhibited similar intensities of  $\alpha$ -tubulin-immunoreactive bands (Fig. 3G). Quantitative immunocytochemistry reveals that INS-1E cells transduced with Ad-EGFP- $\text{Ca}_v3.1$  exhibited significant reduction in the immunofluorescence of syntaxin 1A, SNAP-25, and synaptotagmin III compared to Ad-EGFP-infected cells (Fig. 3I and J). Interestingly, the reduction was efficiently reversed following NNC55-0396 treatment (Fig. 3I and J). However, the critical  $\text{Ca}^{2+}$  sensor synaptotagmin VII that triggers insulin exocytosis only underwent marginal changes following the same treatments (Fig. 3I and J). These results verify that FoxO1 nuclear retention resulting from Ad-EGFP- $\text{Ca}_v3.1$  transduction suppresses transcription of syntaxin 1A, SNAP-25, and synaptotagmin III, which are critical for glucose-stimulated insulin secretion (6, 33–35). This is consistent with the fact that FoxO1 can bind to the promoter regions of SNARE genes and suppress their expression (19).

As a matter of fact, complex interactions between multiple genetic variants and numerous environmental factors result in a number of etiologically heterogeneous subgroups of diabetes (36). Some of them are characterized by derangements in a plethora of molecular and cellular events, including  $\text{Ca}_v$  channel-centered



**Fig. 4.** Model depicting how elevated expression of  $\beta$  cell  $\text{Ca}_v3.1$  channels impairs insulin release and glucose homeostasis. Unphosphorylated FoxO1 can bind to the promoter region of certain exocytotic protein genes to suppress their transcription. Under physiological conditions, however, the transcriptional suppression of FoxO1 hardly occurs since FoxO1 is phosphorylated and extruded from the nucleus to the cytoplasm. This ensures precise transcriptional control, correct differentiation, and adequate insulin secretion capacity of the  $\beta$  cell, thereby maintaining satisfactory glucose homeostasis in the body. Pathologically up-expressed  $\text{Ca}_v3.1$  channels mediate abnormal  $\text{Ca}^{2+}$  influx that constitutively hyperactivates CaN. Constitutively hyperactivated CaN dephosphorylates FoxO1 in nuclei, resulting in its nuclear accumulation. This leads to transcriptional suppression of the exocytotic proteins syntaxin 1A, SNAP-25, and synaptotagmin III, resulting in impaired insulin secretion and aberrant glucose homeostasis. IG, insulin granule.

molecular networks in  $\beta$  cells (6, 37, 38). De novo up-expression of  $\beta$  cell  $\text{Ca}_v3.1$  channels plus pharmacological inhibition and characterization of the eventual ability of these genetically transduced islets to secrete insulin and normalize hyperglycemia enable us to dissect the role of elevated expression of  $\beta$  cell  $\text{Ca}_v3.1$  channels in the development of diabetes from the aforementioned complexity. Furthermore, the combination of such approaches with analysis of the FoxO1 signaling pathway allowed us to identify a pathway from the up-expressed  $\beta$  cell  $\text{Ca}_v3.1$  channels to transcriptional loci suppressing the expression of some exocytotic protein genes in the  $\beta$  cell. Limitations of the present work are due to the difficulty in obtaining islets from a large population of human donors with diabetes for experiments and recruiting sufficient numbers of patients with gain-of-function mutation of the  $\text{Ca}_v3.1$  gene or epigenetic up-regulation of  $\text{Ca}_v3.1$  gene expression for clinical trials. In this context, etiological heterogeneity in diabetes may hinder these basic and clinical studies since small sample sizes can bring about potential bias of experimental results (36). Our work suggests that enhanced expression of  $\beta$  cell  $\text{Ca}_v3.1$  channels plays a causal role in pathogenesis of human diabetes. This remains to be verified by detailed clinical studies.

## Conclusions

We demonstrated the feasibility of using Ad-EGFP- $\text{Ca}_v3.1$  to elevate  $\text{Ca}_v3.1$  channel expression in islets. The elevated expression of  $\text{Ca}_v3.1$  channels not only impairs both basal insulin release and first-phase glucose-stimulated insulin secretion with no influence on second-phase insulin response but also disables islets from normalizing hyperglycemia in STZ-induced diabetic rats. This happens since up-expressed  $\text{Ca}_v3.1$  channels mediate excessive  $\text{Ca}^{2+}$

influx, resulting in pathological elevation of basal  $[\text{Ca}^{2+}]_i$ , which sequentially brings about activation of CaN, dephosphorylation, and nuclear retention of FoxO1 and FoxO1-mediated suppression of syntaxin 1A, SNAP-25, and synaptotagmin III gene transcription in the  $\beta$  cell (Fig. 4). Enhanced T-type  $\text{Ca}^{2+}$  currents through  $\beta$  cell  $\text{Ca}_v3.1$  channels thus play a significant role in the development of a diabetic phenotype and suggest that  $\beta$  cell-specific blockade of these channels may be considered as an approach to treat diabetes.

## Methods

**Animals.** Specific pathogen-free Wistar rats at 8 to 12 wk of age were obtained from Charles River Laboratories (Sulzfeld, Germany) and maintained on a regular light–dark cycle (lights on at 0700 and off at 1900) in temperature- and humidity-controlled rooms and had free access to food pellets and tap water. All animal experiments were conducted according to the guidelines of the Animal Care Committee of Karolinska Institutet.

Additional experimental procedures are presented in the [SI Appendix](#).

**Data Availability.** All of the data, associated protocols, and materials for this study are available within the paper and its [SI Appendix](#).

**ACKNOWLEDGMENTS.** This work was supported by grants from Berth von Kantzow's Foundation, Eurodia (FP6-518153), the ERC-2018-AdG 834860 EYELETS, the Erling-Persson Family Foundation, Karolinska Institutet Funds, the Knut and Alice Wallenberg Foundation, National Natural Science Foundation of China (31500951), Skandia Insurance Company, Ltd., the Stichting af Jochnick Foundation, Strategic Research Program in Diabetes at Karolinska Institutet, Swedish Alzheimer's Association, the Swedish Diabetes Association, Swedish Foundation for Strategic Research, the Swedish Research Council, and the Novo Nordisk Foundation. We thank Ms. Ingela Ahlstedt at AstraZeneca for arranging human islets.

1. N. García-Delgado, M. Velasco, C. Sánchez-Soto, C. M. Díaz-García, M. Hiriart, Calcium channels in postnatal development of rat pancreatic beta cells and their role in insulin secretion. *Front. Endocrinol. (Lausanne)* **9**, 40 (2018).
2. R. González-Ramírez, R. Felix, Transcriptional regulation of voltage-gated  $\text{Ca}^{2+}$  channels. *Acta Physiol. (Oxf.)*, 10.1111/alpha.12883 (2018).
3. W. A. Catterall, Voltage-gated calcium channels. *Cold Spring Harb. Perspect. Biol.* **3**, a003947 (2011).
4. E. Nanou, W. A. Catterall, Calcium channels, synaptic plasticity, and neuropsychiatric disease. *Neuron* **98**, 466–481 (2018).
5. S. N. Yang, P. O. Berggren,  $\text{Ca}_v2.3$  channel and PKC $\alpha$ : New players in insulin secretion. *J. Clin. Invest.* **115**, 16–20 (2005).
6. S. N. Yang, P. O. Berggren, The role of voltage-gated calcium channels in pancreatic  $\beta$ -cell physiology and pathophysiology. *Endocr. Rev.* **27**, 621–676 (2006).
7. S. N. Yang et al., Ionic mechanisms in pancreatic  $\beta$  cell signaling. *Cell. Mol. Life Sci.* **71**, 4149–4177 (2014).
8. G. Santulli et al., Calcium release channel RyR2 regulates insulin release and glucose homeostasis. *J. Clin. Invest.* **125**, 1968–1978 (2015).
9. B. Wu et al., Synaptotagmin-7 phosphorylation mediates GLP-1-dependent potentiation of insulin secretion from  $\beta$ -cells. *Proc. Natl. Acad. Sci. U.S.A.* **112**, 9996–10001 (2015).
10. M. Braun et al., Voltage-gated ion channels in human pancreatic  $\beta$ -cells: Electrophysiological characterization and role in insulin secretion. *Diabetes* **57**, 1618–1628 (2008).
11. A. Bhattacharjee, R. M. Whitehurst Jr, M. Zhang, L. Wang, M. Li, T-type calcium channels facilitate insulin secretion by enhancing general excitability in the insulin-secreting  $\beta$ -cell line, INS-1. *Endocrinology* **138**, 3735–3740 (1997).
12. S. N. Yang, P. O. Berggren,  $\beta$ -cell  $\text{Ca}_v$  channel regulation in physiology and pathophysiology. *Am. J. Physiol. Endocrinol. Metab.* **288**, E16–E28 (2005).
13. H. Zhuang et al., Cloning of a T-type  $\text{Ca}^{2+}$  channel isoform in insulin-secreting cells. *Diabetes* **49**, 59–64 (2000).
14. S. Kato et al., Alterations in basal and glucose-stimulated voltage-dependent  $\text{Ca}^{2+}$  channel activities in pancreatic  $\beta$  cells of non-insulin-dependent diabetes mellitus GK rats. *J. Clin. Invest.* **97**, 2417–2425 (1996).
15. L. Wang, A. Bhattacharjee, J. Fu, M. Li, Abnormally expressed low-voltage-activated calcium channels in  $\beta$ -cells from NOD mice and a related clonal cell line. *Diabetes* **45**, 1678–1683 (1996).
16. F. Rusnak, P. Mertz, Calcineurin: Form and function. *Physiol. Rev.* **80**, 1483–1521 (2000).
17. N. Shioda, F. Han, S. Moriguchi, K. Fukunaga, Constitutively active calcineurin mediates delayed neuronal death through Fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia. *J. Neurochem.* **102**, 1506–1517 (2007).
18. K. K. Cheng et al., APPL1 potentiates insulin secretion in pancreatic  $\beta$  cells by enhancing protein kinase Akt-dependent expression of SNARE proteins in mice. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 8919–8924 (2012).
19. K. Kaneko et al., Class IA phosphatidylinositol 3-kinase in pancreatic  $\beta$  cells controls insulin secretion by multiple mechanisms. *Cell. Metab.* **12**, 619–632 (2010).
20. Y. Lu et al., Mibefradil reduces blood glucose concentration in db/db mice. *Clinics (São Paulo)* **69**, 61–67 (2014).
21. Y. P. Zhou et al., Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets. A common mechanism for glucose toxicity and lipotoxicity? *J. Biol. Chem.* **278**, 51316–51323 (2003).
22. R. I. Mahato et al., Cationic lipid and polymer-based gene delivery to human pancreatic islets. *Mol. Ther.* **7**, 89–100 (2003).
23. T. C. Südhof, Calcium control of neurotransmitter release. *Cold Spring Harb. Perspect. Biol.* **4**, a011353 (2012).
24. T. C. Südhof, J. E. Rothman, Membrane fusion: Grappling with SNARE and SM proteins. *Science* **323**, 474–477 (2009).
25. Z. P. Pang, T. C. Südhof, Cell biology of  $\text{Ca}^{2+}$ -triggered exocytosis. *Curr. Opin. Cell Biol.* **22**, 496–505 (2010).
26. E. Cerasi, R. Luft, The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus. *Acta Endocrinol. (Copenh.)* **55**, 278–304 (1967).
27. E. Cerasi, R. Luft, S. Efendic, Decreased sensitivity of the pancreatic  $\beta$  cells to glucose in prediabetic and diabetic subjects. A glucose dose-response study. *Diabetes* **21**, 224–234 (1972).
28. D. S. Bell, Importance of postprandial glucose control. *South. Med. J.* **94**, 804–809 (2001).
29. S. N. Yang, P. O. Berggren, The eye as a novel imaging site in diabetes research. *Pharmacol. Ther.* **197**, 103–121 (2019).
30. M. Szabat et al., Maintenance of  $\beta$ -cell maturity and plasticity in the adult pancreas: Developmental biology concepts in adult physiology. *Diabetes* **61**, 1365–1371 (2012).
31. C. Talchai, S. Xuan, H. V. Lin, L. Sussel, D. Accili, Pancreatic  $\beta$  cell dedifferentiation as a mechanism of diabetic  $\beta$  cell failure. *Cell* **150**, 1223–1234 (2012).
32. P. Lipton, Ischemic cell death in brain neurons. *Physiol. Rev.* **79**, 1431–1568 (1999).
33. H. Brown et al., Synaptotagmin III isoform is compartmentalized in pancreatic beta-cells and has a functional role in exocytosis. *Diabetes* **49**, 383–391 (2000).
34. J. Ji et al., Modulation of L-type  $\text{Ca}^{2+}$  channels by distinct domains within SNAP-25. *Diabetes* **51**, 1425–1436 (2002).
35. S. N. Yang et al., Syntaxin 1 interacts with the  $\text{L}_D$  subtype of voltage-gated  $\text{Ca}^{2+}$  channels in pancreatic  $\beta$  cells. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 10164–10169 (1999).
36. R. A. DeFronzo et al., Type 2 diabetes mellitus. *Nat. Rev. Dis. Primers* **1**, 15019 (2015).
37. P. A. Halban et al.,  $\beta$ -cell failure in type 2 diabetes: Postulated mechanisms and prospects for prevention and treatment. *Diabetes Care* **37**, 1751–1758 (2014).
38. L. I. Hudish, J. E. Reusch, L. Sussel,  $\beta$  cell dysfunction during progression of metabolic syndrome to type 2 diabetes. *J. Clin. Invest.* **129**, 4001–4008 (2019).